Rebound COVID symptoms-runny nose, nasal congestion, fatigue and positive at home test. This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Rebound COVID symptoms-runny nose, nasal congestion, fatigue and positive at home test.) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 057M21RS) for COVID-19 vaccination.     Concurrent medical conditions included High cholesterol (Borderline high cholesterol), Allergy to antibiotic (Allergic to Amoxicillin) and Pollen allergy. Concomitant products included SIMVASTATIN from January 2015 to 19-May-2022 for an unknown indication.    On 02-May-2022 at 10:30 AM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Rebound COVID symptoms-runny nose, nasal congestion, fatigue and positive at home test.). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 20-May-2022 to 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency and FEXOFENADINE at an unspecified dose and frequency. At the time of the report, COVID-19 (Rebound covid symptoms-runny nose, nasal congestion, fatigue and positive at home test.) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Jun-2022, SARS-CoV-2 test: positive (Positive) rebound COVID symptoms and Positive at home test.         It was reported that the patient was taking any other medications/products within 2 weeks of starting COVID-19 treatment and the patient previously received a COVID-19 Vaccine.  The patient experienced rebound of COVID symptoms- runny nose, nasal congestion, fatigue - and was tested positive at home test on 01-Jun-2022 at 17:00.  For symptomatic relief, the patient took fexofenadine   The device date reported as 02-Jun-2022.  Company Comment:  This is a spontaneous case concerning  a  66-year-old, male patient with no relevant medical history, who experienced the unexpected non-serious RA event of Covid-19. The event occurred on an unknown date. It was reported that patient was administered on May 2, 2022 for the fourth dose of mRNA-1273 COVID 19 Vaccine. Patient was treated with nirmatrelvir, ritonavir at an unspecified dose and frequency. COVID-19 diagnosis was confirmed with an antigen test. The event was reported as not resolved The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report. Event terms, seriousness criteria and product information were captured as provided.; Sender's Comments: Company Comment:  This is a spontaneous case concerning  a  66-year-old, male patient with no relevant medical history, who experienced the unexpected non-serious RA event of Covid-19. The event occurred on an unknown date. It was reported that patient was administered on May 2, 2022 for the fourth dose of mRNA-1273 COVID 19 Vaccine. Patient was treated with nirmatrelvir, ritonavir at an unspecified dose and frequency. COVID-19 diagnosis was confirmed with an antigen test. The event was reported as not resolved The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report. Event terms, seriousness criteria and product information were captured as provided.